253 related articles for article (PubMed ID: 29221790)
1. FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes.
Zhang X; Yang W; Wang J; Meng Y; Guan Y; Yang J
Metabolism; 2018 Apr; 81():71-82. PubMed ID: 29221790
[TBL] [Abstract][Full Text] [Related]
2. Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease.
Yang J; Guan Y
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():105-11. PubMed ID: 23855304
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
4. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
[TBL] [Abstract][Full Text] [Related]
5. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.
Wang C; Chi Y; Li J; Miao Y; Li S; Su W; Jia S; Chen Z; Du S; Zhang X; Zhou Y; Wu W; Zhu M; Wang Z; Yang H; Xu G; Wang S; Yang J; Guan Y
Hepatology; 2014 May; 59(5):1779-90. PubMed ID: 24806753
[TBL] [Abstract][Full Text] [Related]
6. FAM3C activates HSF1 to suppress hepatic gluconeogenesis and attenuate hyperglycemia of type 1 diabetic mice.
Chen Z; Wang J; Yang W; Chen J; Meng Y; Feng B; Chi Y; Geng B; Zhou Y; Cui Q; Yang J
Oncotarget; 2017 Dec; 8(62):106038-106049. PubMed ID: 29285313
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
8. Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.
Liu X; Hou S; Xiang R; Hu C; Chen Z; Li N; Yan H; Yu X; Li X; Chi Y; Yang J
Metabolism; 2022 Nov; 136():155292. PubMed ID: 35995281
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation.
Hu Y; Li J; Li X; Wang D; Xiang R; Liu W; Hou S; Zhao Q; Yu X; Xu M; Zhao D; Li T; Chi Y; Yang J
Metabolism; 2023 Sep; 146():155661. PubMed ID: 37454871
[TBL] [Abstract][Full Text] [Related]
10. FAM3 Family as Prognostic Factors for Head and Neck Squamous Cell Carcinoma.
Liao C; Wang Q; An J; Wang H; Xiao L; Long Q; Zhao H; Liu J; Guan X
Comb Chem High Throughput Screen; 2023; 26(3):539-558. PubMed ID: 35538834
[TBL] [Abstract][Full Text] [Related]
11. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
12. FAM3A maintains metabolic homeostasis by interacting with F1-ATP synthase to regulate the activity and assembly of ATP synthase.
Yan H; Meng Y; Li X; Xiang R; Hou S; Wang J; Wang L; Yu X; Xu M; Chi Y; Yang J
Metabolism; 2023 Feb; 139():155372. PubMed ID: 36470472
[TBL] [Abstract][Full Text] [Related]
13. Repurposing Doxepin to Ameliorate Steatosis and Hyperglycemia by Activating FAM3A Signaling Pathway.
Chen Z; Liu X; Luo Y; Wang J; Meng Y; Sun L; Chang Y; Cui Q; Yang J
Diabetes; 2020 Jun; 69(6):1126-1139. PubMed ID: 32312868
[TBL] [Abstract][Full Text] [Related]
14. Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
Veiga FMS; Graus-Nunes F; Rachid TL; Barreto AB; Mandarim-de-Lacerda CA; Souza-Mello V
Biochimie; 2017 Sep; 140():106-116. PubMed ID: 28711683
[TBL] [Abstract][Full Text] [Related]
15. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
16. FAM3A enhances adipogenesis of 3T3-L1 preadipocytes via activation of ATP-P2 receptor-Akt signaling pathway.
Chi Y; Li J; Li N; Chen Z; Ma L; Peng W; Pan X; Li M; Yu W; He X; Geng B; Cui Q; Liu Y; Yang J
Oncotarget; 2017 Jul; 8(28):45862-45873. PubMed ID: 28515350
[TBL] [Abstract][Full Text] [Related]
17. Ellagic Acid Alleviates Hepatic Oxidative Stress and Insulin Resistance in Diabetic Female Rats.
Polce SA; Burke C; França LM; Kramer B; de Andrade Paes AM; Carrillo-Sepulveda MA
Nutrients; 2018 Apr; 10(5):. PubMed ID: 29693586
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway.
Li J; Chi Y; Wang C; Wu J; Yang H; Zhang D; Zhu Y; Wang N; Yang J; Guan Y
Hepatology; 2011 Jun; 53(6):1906-16. PubMed ID: 21412813
[TBL] [Abstract][Full Text] [Related]
19. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
